-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
[Pharmaceutical Network Market Analysis] According to the schedule, the results of the seventh batch of national procurement of drugs that affect the nerves of every medical person will be released today (July 12) in Nanjing, Jiang.
In the first six batches of national procurement of drugs, 234 drugs were included in the centralized procurement, with an average drop of 53%, saving medical expenses by more than 260 billion yuan, and effectively reducing the burden of medical treatment for the mass.
So, what are the points of view of this national mining? A total of 61 kinds of drugs were included The seventh batch of drugs included a total of 61 kinds of drugs with 125 product specifications, including drugs for chronic diseases such as hypertension and diabetes, as well as drugs for common diseases such as anti-infection, as well as drugs for lung cancer, liver cancer, kidney cancer, and bowel canc.
There are many kinds of drugs for major diseases such as oseltamivir oral regular-release dosage form, hepatitis B drug tenofovir alafenamide oral regular-release dosage form, antihypertensive drug nifedipine controlled-release dosage form, e.
, the benefit of the masses is very wi.
According to other related reports, as of now, about 298 companies have participated in the bid opening meeting for this batch of national centralized drug procurement, including Huahai Pharmaceutical and AstraZene.
The rules of centralized procurement have chang.
Compared with the previous six batches of national procurement, this centralized procurement adhered to the basic principle of "linking volume and price, integrating recruitment and procurement" and the working mechanism of "national organization, alliance procurement, and platform operation", and made further improvemen.
Adjustment and optimization and strengthening of supply guarantee are conducive to the implementation of centralized procurement results that are more operational and more in line with the actual market usage of varieti.
For example, in order to ensure the supply of the selected drugs, this centralized procurement no longer follows the previous rule that there is only one successful bidder for a drug in a province, but introduces a backup supply mechanism, that is, a “dual supply” guarantee supply model in one provin.
Each province will have one main supply company and one standby supply company at the same ti.
When the main supply company cannot supply enough in time or is disqualified from being selected, it can switch to the standby supply company in time to ensure stable clinical use, thereby further reducing The selected drugs may be cut off due to various reaso.
Strengthen the supervision of the selected enterprises This centralized procurement requires the selected enterprises to continue to have domestic valid registration approval documents for the selected drugs during the performance of the contract, which further strengthens the responsibility of the selected enterprises to perform the contra.
At the same time, the supervision of the selected enterprises has been strengthened, and enterprises that are clearly judged to be "serious" or "extraordinarily serious" dishonest grades or enterprises that have been disqualified from the selection by the joint procurement office within two years of centralized procurement, after obtaining the qualifications to be selected, the main supply and In the confirmation of the ready-to-supply area, none of them have the qualification to select the confirmed area for the first time, that is, there is relatively one less supply ar.
This rule further deepens the application and intensity of the recruitment and procurement credit syst.
"Involution" or intensification The industry predicts that the "involution" of this national procurement is expected to intensify, because of the 61 drug varieties adopted by the country this time, more than 10 companies are eligible to "enter the marke.
Among them, the most fierce competition is expected to be omeprazole injecti.
A total of 28 companies, including the original AstraZeneca, have obtained the qualification for centralized procurement, but according to the rules, only 10 companies can be select.
It is foreseeable that the competition of this variety will be fier.
In addition, there are more than 10 companies qualified for the application of oseltamivir oral normal-release dosage for.
The original research of this variety is Roche, and domestic pharmaceutical companies include Sunshine Pharmaceuticals, Qilu Pharmaceuticals, Kelun Pharmaceuticals, and Borui Pharmaceutica.
According to the State Food and Drug Administration's "Information Release of Drug Approval Documents to be Obtained on July 08, 2022", on July 7, Huahai Pharmaceutical, Zhongshan Wanhan Pharmaceutical and Xidelong Pharmaceutical all received osmium phosphate Approval for Tasvir Capsul.
Huahai Pharmaceutical stated in its announcement on July 8 that Oseltamivir Phosphate Capsules obtained the "Drug Registration Certificate" from the State Food and Drug Administration, marking the company's qualification to sell the drug in the domestic market and further enriching the company's produc.
line, which helps to enhance the market competitiveness of the company's produc.
According to the relevant national policies, the company's approved production of oseltamivir phosphate capsules according to Category 4 chemicals can be regarded as the same revi.
Medical institutions will give priority to purchase and use them in clinical practice, which is conducive to expanding the market sales of products and has a positive impact on the company's operati.
positive impact on performan.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyo.
In the first six batches of national procurement of drugs, 234 drugs were included in the centralized procurement, with an average drop of 53%, saving medical expenses by more than 260 billion yuan, and effectively reducing the burden of medical treatment for the mass.
So, what are the points of view of this national mining? A total of 61 kinds of drugs were included The seventh batch of drugs included a total of 61 kinds of drugs with 125 product specifications, including drugs for chronic diseases such as hypertension and diabetes, as well as drugs for common diseases such as anti-infection, as well as drugs for lung cancer, liver cancer, kidney cancer, and bowel canc.
There are many kinds of drugs for major diseases such as oseltamivir oral regular-release dosage form, hepatitis B drug tenofovir alafenamide oral regular-release dosage form, antihypertensive drug nifedipine controlled-release dosage form, e.
, the benefit of the masses is very wi.
According to other related reports, as of now, about 298 companies have participated in the bid opening meeting for this batch of national centralized drug procurement, including Huahai Pharmaceutical and AstraZene.
The rules of centralized procurement have chang.
Compared with the previous six batches of national procurement, this centralized procurement adhered to the basic principle of "linking volume and price, integrating recruitment and procurement" and the working mechanism of "national organization, alliance procurement, and platform operation", and made further improvemen.
Adjustment and optimization and strengthening of supply guarantee are conducive to the implementation of centralized procurement results that are more operational and more in line with the actual market usage of varieti.
For example, in order to ensure the supply of the selected drugs, this centralized procurement no longer follows the previous rule that there is only one successful bidder for a drug in a province, but introduces a backup supply mechanism, that is, a “dual supply” guarantee supply model in one provin.
Each province will have one main supply company and one standby supply company at the same ti.
When the main supply company cannot supply enough in time or is disqualified from being selected, it can switch to the standby supply company in time to ensure stable clinical use, thereby further reducing The selected drugs may be cut off due to various reaso.
Strengthen the supervision of the selected enterprises This centralized procurement requires the selected enterprises to continue to have domestic valid registration approval documents for the selected drugs during the performance of the contract, which further strengthens the responsibility of the selected enterprises to perform the contra.
At the same time, the supervision of the selected enterprises has been strengthened, and enterprises that are clearly judged to be "serious" or "extraordinarily serious" dishonest grades or enterprises that have been disqualified from the selection by the joint procurement office within two years of centralized procurement, after obtaining the qualifications to be selected, the main supply and In the confirmation of the ready-to-supply area, none of them have the qualification to select the confirmed area for the first time, that is, there is relatively one less supply ar.
This rule further deepens the application and intensity of the recruitment and procurement credit syst.
"Involution" or intensification The industry predicts that the "involution" of this national procurement is expected to intensify, because of the 61 drug varieties adopted by the country this time, more than 10 companies are eligible to "enter the marke.
Among them, the most fierce competition is expected to be omeprazole injecti.
A total of 28 companies, including the original AstraZeneca, have obtained the qualification for centralized procurement, but according to the rules, only 10 companies can be select.
It is foreseeable that the competition of this variety will be fier.
In addition, there are more than 10 companies qualified for the application of oseltamivir oral normal-release dosage for.
The original research of this variety is Roche, and domestic pharmaceutical companies include Sunshine Pharmaceuticals, Qilu Pharmaceuticals, Kelun Pharmaceuticals, and Borui Pharmaceutica.
According to the State Food and Drug Administration's "Information Release of Drug Approval Documents to be Obtained on July 08, 2022", on July 7, Huahai Pharmaceutical, Zhongshan Wanhan Pharmaceutical and Xidelong Pharmaceutical all received osmium phosphate Approval for Tasvir Capsul.
Huahai Pharmaceutical stated in its announcement on July 8 that Oseltamivir Phosphate Capsules obtained the "Drug Registration Certificate" from the State Food and Drug Administration, marking the company's qualification to sell the drug in the domestic market and further enriching the company's produc.
line, which helps to enhance the market competitiveness of the company's produc.
According to the relevant national policies, the company's approved production of oseltamivir phosphate capsules according to Category 4 chemicals can be regarded as the same revi.
Medical institutions will give priority to purchase and use them in clinical practice, which is conducive to expanding the market sales of products and has a positive impact on the company's operati.
positive impact on performan.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyo.
